Cephalexin products in the United States can be associated with several companies appearing in FDA approval records or DailyMed labels. Those names can describe distinct roles: drug-application holder, labeler, physical manufacturer, distributor, packager or relabeler. A meaningful manufacturer directory should keep these roles separate instead of pretending that every company printed on a bottle made the drug.
This index explains how to investigate records for companies such as Teva, Aurobindo, Lupin and Ascend. It does not rank manufacturers by quality or claim that named products are in every retail pharmacy.
For a real prescription, the pharmacist can confirm the dispensed NDC, active ingredient, strength and labeler and can help resolve questions about a manufacturer change. Regulatory listings need to be read in their proper context: an FDA NDC listing alone is not proof of FDA approval or live stock.
The FDA application holder is the legal entity associated with an approved application; the labeler submits product listing information; a contract manufacturer may physically make the medicine; a distributor manages sale and movement; and a repackager or relabeler may place a product in another package.
These roles can overlap but should not be treated as synonyms. For a suspicious or unfamiliar label, verify all relevant entities before making claims about origin.
A systematic manufacturer comparison can use four fields: company shown as labeler, application holder where documented, manufacturing statement, and product NDC. Those fields answer different questions. A pharmacist can also identify a source NDC in a repackaged product, which helps explain why more than one company name appears in public records.
| Your next question | Relevant Core guide | What it covers |
|---|---|---|
| Company-specific capsules | Teva | Review capsule labeling and status |
| Company capsules and liquid | Aurobindo | See U.S. capsule and suspension labels |
| Capsules and suspension | Lupin | Distinguish source and repackagers |
| Packager and distributor roles | Ascend | Interpret labeled products |
| Need equivalent products | Substitution | Learn product-matching safeguards |
Teva Pharmaceuticals USA appears as packager in a DailyMed cephalexin capsule label. Its recorded capsule product information can help identify the form and prescribing context, but the public label is not a warehouse count.
The dedicated Teva cephalexin guide handles company-specific capsules, label version and NDC verification rather than reproducing generic cephalexin marketing claims.
Aurobindo has U.S. cephalexin capsule labeling and separate 2026 oral-suspension records describing 125 mg/5 mL and 250 mg/5 mL presentations. Those records illustrate why a manufacturer index should identify the exact dosage form, not simply list a company as “making cephalexin.”
For company details and the distinction between application and U.S. distribution, use Aurobindo cephalexin.
For Aurobindo, it is useful to keep the 2026 suspension labels separate from capsule documents. They are not simply different photographs of the same product; the liquid requires concentration and bottle-volume identification. This distinction gives the Aurobindo page a separate purpose from a capsule-only manufacturer profile.
Lupin-associated cephalexin records include capsules and oral suspension. The specific label and NDC should be checked because repackaged products can introduce other company names even when the source is associated with Lupin.
Review Lupin cephalexin for the product-specific label and manufacturer distinction. Do not interpret an old DailyMed image as proof of present-day local availability.
Ascend Laboratories appears as packager for capsule and suspension labels. In suspension documentation, another company may be listed as the physical manufacturer while Ascend is the U.S. distributor. This is a direct example of why the labeler name is not always the factory name.
See Ascend cephalexin products for the relevant distinction and the concentration-specific suspension records.
For Ascend suspension, the public label naming Alkem as manufacturer illustrates the danger of casually saying “made by Ascend.” Describing the actual documented relationship is more informative than compiling a long list of company logos or headquarters countries. The data should help a reader interpret the pack in hand.
The Orange Book is the principal source for approved product applications and therapeutic-equivalence evaluation. It helps identify the appropriate product type and applicant. A drug appearing in a label search may not reveal all of its approval and marketing context without an additional check.
Compare approval details against the form and strength the pharmacy is actually offering, and avoid treating legacy brand entries as current stock.
DailyMed hosts structured labels, including active ingredient, dosing form, package presentation, packager and, in many cases, manufacturing details. Labels may be revised and multiple entries can exist for the same active ingredient or a repackaged source.
Capture the set ID and version when checking a specific product; a company-name search alone can show unrelated or obsolete items.
A National Drug Code identifies a listed product and may include package details, but FDA states that the presence of an NDC does not itself confirm drug approval, insurance coverage or independent verification of labeler-submitted facts.
Check the NDC against the printed package and applicable approval record; for availability, ask a licensed pharmacy directly. Stock-checking guidance is a separate practical workflow.
A repackaged product can carry an NDC from the repackager and include a source identifier for the original product. These cross-references are especially useful when a drug is dispensed in a unit-dose pouch or other nonoriginal packaging. They do not necessarily mean a new antibiotic was manufactured.
A pharmacy may use an eligible generic from another labeler when an earlier manufacturer is not the item being dispensed. Whether a change is permitted requires matching the ingredient, dosage form, strength and appropriate equivalence status.
A different imprint or color should trigger verification, not panic or automatic rejection. Consult the substitution guide for what the pharmacy should check.
All FDA-approved manufacturers are subject to applicable quality rules, but an online directory cannot rank the quality of specific current batches from the brand name alone. Likewise, a company’s country of incorporation does not determine if its U.S. approved product meets standards.
Avoid claims that a manufacturer is uniquely safest, cheapest or always in stock without compelling specific evidence.
Record the exact active ingredient, dosage form, strength, product NDC, application where relevant, labeler, manufacturing statement and pharmacy source. Cross-check FDA and DailyMed before drawing conclusions about a company’s role.
A labeled presentation is not the same as a confirmed in-stock prescription offer. Where commercial links exist on this site, they are partner relationships rather than manufacturer endorsements.
Multiple companies appear in FDA or DailyMed records, including Teva, Aurobindo, Lupin and Ascend in different product or labeling roles.
No. The entity on the package can be a distributor, relabeler or packager; the physical manufacturer may be different.
No. Published product records do not confirm pharmacy inventory or a particular wholesaler supply.
Yes. Application holders, manufacturers, distributors and repackagers can differ.
No. FDA says NDC listing by itself is not an approval determination.
They may be able to dispense an eligible equivalent under applicable law and prescription instructions; ask the pharmacist to verify the product.
No. Product families and strengths vary by company and regulatory record.
No. It organizes verifiable records without making unsupported quality or availability rankings.